News
all
press releases
Revance Therapeutics Stock’s Retail Sentiment Muted Even As Teoxane Makes Better Offer Than Crown Labs
The offer represents a 16% premium over the $3.10-per-share agreement with Crown Laboratories announced last month.
Stocktwits
Revance Therapeutics Stock Plummets To 4-Month Low As Crown Labs Halves Takeover Offer: Retail Fumes
The price cut follows a notice received by Revance in September alleging violations of an exclusive distribution agreement with Teoxane.
Stocktwits

Advertisement|Remove ads.